Q32 Bio (FIXX) Stock Forecast, Price Target & Predictions

FIXX Stock Forecast

Q32 Bio stock forecast is as follows: an average price target of $2.70 (represents a 188.86% upside from FIXX’s last price of $0.93) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

FIXX Price Target

The average price target for Q32 Bio (FIXX) is $2.70 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $2.70 to $2.70. This represents a potential 188.86% upside from FIXX's last price of $0.93.

FIXX Analyst Ratings

Buy

According to 4 Wall Street analysts, Q32 Bio's rating consensus is 'Buy'. The analyst rating breakdown for FIXX stock is 0 'Strong Buy' (0.00%), 2 'Buy' (50.00%), 2 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Q32 Bio Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Apr 28, 2022		Credit Suisse	$2.70	$1.61	67.70%	188.86%

The latest Q32 Bio stock forecast, released on Apr 28, 2022 by Credit Suisse company, set a price target of $2.70, which represents a 67.70% increase from the stock price at the time of the forecast ($1.61), and a 188.86% increase from FIXX last price ($0.93).

Q32 Bio Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	-
Avg Price Target	-	-	-
Last Closing Price	$0.93	$0.93	$0.93
Upside/Downside	-100.00%	-100.00%	-100.00%

In the current month, the average price target of Q32 Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Q32 Bio's last price of $0.93. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Apr 28, 2022	Credit Suisse		Neutral	Initialise
Feb 22, 2022	Chardan Capital	Buy	Buy	Hold
Feb 22, 2022	BTIG	Buy	Buy	Hold
Feb 22, 2022	RBC Capital		Sector Perform	Downgrade
Feb 22, 2022	Oppenheimer		Perform	Downgrade

Q32 Bio's last stock rating was published by Credit Suisse on Apr 28, 2022. The company Initialise its FIXX rating from "null" to "Neutral".

Q32 Bio Financial Forecast

Q32 Bio Revenue Forecast

	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19	Oct 19	Jul 19	Mar 19	Mar 18
Revenue	-	-	-	-	-	-	-	$802.00K	$802.00K	-	-	$802.00K	$802.00K	-	-	$29.30M	$980.00K	-	-	$588.00K	$563.00K	-	-	$270.00K	$823.37K
Avg Forecast	$500.00K	$500.00K	$500.00K	$500.00K	$500.00K	$500.00K	$830.50K	$1.01M	$830.60K	$860.60K	$1.00M	$7.21M	$853.00K	$643.70K	$429.70K	$576.86K	$1.22M	$573.00K	$491.14K	$580.00K	$1.37M	$490.00K	$800.00K	$975.00K	$729.71K
High Forecast	$500.00K	$500.00K	$500.00K	$500.00K	$500.00K	$500.00K	$830.50K	$1.01M	$830.60K	$860.60K	$1.00M	$7.21M	$853.00K	$643.70K	$429.70K	$576.86K	$1.22M	$573.00K	$491.14K	$580.00K	$1.37M	$490.00K	$800.00K	$975.00K	$875.65K
Low Forecast	$500.00K	$500.00K	$500.00K	$500.00K	$500.00K	$500.00K	$830.50K	$1.01M	$830.60K	$860.60K	$1.00M	$7.21M	$853.00K	$643.70K	$429.70K	$576.86K	$1.22M	$573.00K	$491.14K	$580.00K	$1.37M	$490.00K	$800.00K	$975.00K	$583.76K
# Analysts	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	10	10	10	10	9	9	9	9	20
Surprise %	-	-	-	-	-	-	-	0.79%	0.97%	-	-	0.11%	0.94%	-	-	50.80%	0.80%	-	-	1.01%	0.41%	-	-	0.28%	1.13%

Q32 Bio's average Quarter revenue forecast for Jul 23 based on 1 analysts is $830.50K, with a low forecast of $830.50K, and a high forecast of $830.50K. FIXX's average Quarter revenue forecast represents a 3.55% increase compared to the company's last Quarter revenue of $802.00K (Mar 23).

Q32 Bio EBITDA Forecast

	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19	Oct 19	Jul 19	Mar 19	Mar 18
# Analysts	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	10	10	10	10	9	9	9	9	20
EBITDA	-	-	-	-	-	-	-	$-27.29M	$-34.20M	-	-	$-168.52M	$-31.51M	-	-	$1.01M	$-27.73M	-	-	$-33.20M	$-22.45M	-	-	$-22.59M	$-10.30M
Avg Forecast	$-500.00K	$-500.00K	$-500.00K	$-500.00K	$-500.00K	$-500.00K	$-830.50K	$-1.01M	$-830.60K	$-860.60K	$-1.00M	$-7.21M	$-853.00K	$-643.70K	$-429.70K	$-576.86K	$-1.22M	$-573.00K	$-491.14K	$-28.32M	$-1.37M	$-490.00K	$-800.00K	$-17.90M	$-9.13M
High Forecast	$-500.00K	$-500.00K	$-500.00K	$-500.00K	$-500.00K	$-500.00K	$-830.50K	$-1.01M	$-830.60K	$-860.60K	$-1.00M	$-7.21M	$-853.00K	$-643.70K	$-429.70K	$-576.86K	$-1.22M	$-573.00K	$-491.14K	$-22.66M	$-1.37M	$-490.00K	$-800.00K	$-14.32M	$-7.30M
Low Forecast	$-500.00K	$-500.00K	$-500.00K	$-500.00K	$-500.00K	$-500.00K	$-830.50K	$-1.01M	$-830.60K	$-860.60K	$-1.00M	$-7.21M	$-853.00K	$-643.70K	$-429.70K	$-576.86K	$-1.22M	$-573.00K	$-491.14K	$-33.98M	$-1.37M	$-490.00K	$-800.00K	$-21.48M	$-10.96M
Surprise %	-	-	-	-	-	-	-	26.89%	41.17%	-	-	23.38%	36.94%	-	-	-1.75%	22.71%	-	-	1.17%	16.43%	-	-	1.26%	1.13%

1 analysts predict FIXX's average Quarter EBITDA for Jul 21 to be $-429.70K, with a high of $-429.70K and a low of $-429.70K. This is -142.67% lower than Q32 Bio's previous annual EBITDA (Mar 21) of $1.01M.

Q32 Bio Net Income Forecast

	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19	Oct 19	Jul 19	Mar 19	Mar 18
# Analysts	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	10	10	10	10	9	9	9	9	20
Net Income	-	-	-	-	-	-	-	$-28.84M	$-32.94M	-	-	$92.11M	$-33.58M	-	-	$-1.07M	$-29.79M	-	-	$-35.33M	$-24.17M	-	-	$-23.85M	$-10.52M
Avg Forecast	$-326.79K	$-350.13K	$-396.81K	$-536.86K	$-700.25K	$-980.36K	$-1.10M	$-1.24M	$-1.15M	$-1.07M	$-1.25M	$542.37M	$-1.34M	$-1.37M	$-1.34M	$-1.90M	$-1.54M	$-1.89M	$-1.73M	$-30.14M	$-1.59M	$-1.40M	$-1.28M	$-18.90M	$-9.33M
High Forecast	$-326.79K	$-350.13K	$-396.81K	$-536.86K	$-700.25K	$-980.36K	$-1.10M	$-1.24M	$-1.15M	$-1.07M	$-1.25M	$650.84M	$-1.34M	$-1.37M	$-1.34M	$-1.52M	$-1.54M	$-1.89M	$-1.73M	$-24.11M	$-1.59M	$-1.40M	$-1.28M	$-15.12M	$-7.46M
Low Forecast	$-326.79K	$-350.13K	$-396.81K	$-536.86K	$-700.25K	$-980.36K	$-1.10M	$-1.24M	$-1.15M	$-1.07M	$-1.25M	$433.89M	$-1.34M	$-1.37M	$-1.34M	$-2.28M	$-1.54M	$-1.89M	$-1.73M	$-36.16M	$-1.59M	$-1.40M	$-1.28M	$-22.68M	$-11.19M
Surprise %	-	-	-	-	-	-	-	23.32%	28.67%	-	-	0.17%	25.05%	-	-	0.56%	19.37%	-	-	1.17%	15.16%	-	-	1.26%	1.13%

Q32 Bio's average Quarter net income forecast for Jul 22 is $-1.25M, with a range of $-1.25M to $-1.25M. FIXX's average Quarter net income forecast represents a -101.36% decrease compared to the company's last Quarter net income of $92.11M (Mar 22).

Q32 Bio SG&A Forecast

	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19	Oct 19	Jul 19	Mar 19	Mar 18
# Analysts	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	10	10	10	10	9	9	9	9	20
SG&A	-	-	-	-	-	-	-	$8.32M	$8.15M	-	-	$14.15M	$10.78M	-	-	$8.66M	$7.59M	-	-	$7.77M	$5.78M	-	-	$4.86M	$3.83M
Avg Forecast	$6.49M	$6.49M	$6.49M	$6.49M	$6.49M	$6.49M	$10.78M	$13.17M	$10.78M	$11.17M	$12.99M	$93.55M	$11.07M	$8.35M	$5.58M	$7.49M	$15.85M	$7.44M	$6.37M	$7.53M	$17.74M	$6.36M	$10.38M	$12.66M	$9.47M
High Forecast	$6.49M	$6.49M	$6.49M	$6.49M	$6.49M	$6.49M	$10.78M	$13.17M	$10.78M	$11.17M	$12.99M	$93.55M	$11.07M	$8.35M	$5.58M	$7.49M	$15.85M	$7.44M	$6.37M	$7.53M	$17.74M	$6.36M	$10.38M	$12.66M	$11.37M
Low Forecast	$6.49M	$6.49M	$6.49M	$6.49M	$6.49M	$6.49M	$10.78M	$13.17M	$10.78M	$11.17M	$12.99M	$93.55M	$11.07M	$8.35M	$5.58M	$7.49M	$15.85M	$7.44M	$6.37M	$7.53M	$17.74M	$6.36M	$10.38M	$12.66M	$7.58M
Surprise %	-	-	-	-	-	-	-	0.63%	0.76%	-	-	0.15%	0.97%	-	-	1.16%	0.48%	-	-	1.03%	0.33%	-	-	0.38%	0.40%

Q32 Bio's average Quarter SG&A projection for Jul 23 is $10.78M, based on 1 Wall Street analysts, with a range of $10.78M to $10.78M. The forecast indicates a 29.48% rise compared to FIXX last annual SG&A of $8.32M (Mar 23).

Q32 Bio EPS Forecast

	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19	Oct 19	Jul 19	Mar 19	Mar 18
# Analysts	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	10	10	10	10	9	9	9	9	20
EPS	-	-	-	-	-	-	-	$-0.50	$-0.57	-	-	$1.61	$-0.59	-	-	$-0.02	$-0.66	-	-	$-0.78	$-0.54	-	-	$-0.64	$-4.21
Avg Forecast	$-0.14	$-0.15	$-0.17	$-0.23	$-0.30	$-0.42	$-0.47	$-0.53	$-0.49	$-0.46	$-0.54	$-0.49	$-0.57	$-0.59	$-0.57	$-0.61	$-0.66	$-0.81	$-0.74	$-0.69	$-0.68	$-0.60	$-0.55	$-0.54	$-3.35
High Forecast	$-0.14	$-0.15	$-0.17	$-0.23	$-0.30	$-0.42	$-0.47	$-0.53	$-0.49	$-0.46	$-0.54	$-0.49	$-0.57	$-0.59	$-0.57	$-0.61	$-0.66	$-0.81	$-0.74	$-0.69	$-0.68	$-0.60	$-0.55	$-0.54	$-2.68
Low Forecast	$-0.14	$-0.15	$-0.17	$-0.23	$-0.30	$-0.42	$-0.47	$-0.53	$-0.49	$-0.46	$-0.54	$-0.49	$-0.57	$-0.59	$-0.57	$-0.61	$-0.66	$-0.81	$-0.74	$-0.69	$-0.68	$-0.60	$-0.55	$-0.54	$-4.02
Surprise %	-	-	-	-	-	-	-	0.94%	1.16%	-	-	-3.27%	1.03%	-	-	0.03%	1.00%	-	-	1.13%	0.78%	-	-	1.19%	1.26%

According to 1 Wall Street analysts, Q32 Bio's projected average Quarter EPS for Jul 22 is $-0.54, with a low estimate of $-0.54 and a high estimate of $-0.54. This represents a -133.39% decrease compared to FIXX previous annual EPS of $1.61 (Mar 22).

Q32 Bio Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
PASG	Passage Bio	$0.67	$6.00	795.52%	Buy
BDTX	Black Diamond Therapeutics	$2.50	$20.00	700.00%	Buy
ADAP	Adaptimmune Therapeutics	$0.60	$4.00	566.67%	Buy
FDMT	4D Molecular Therapeutics	$6.32	$38.33	506.49%	Buy
STOK	Stoke Therapeutics	$12.10	$26.50	119.01%	Buy

FIXX Forecast FAQ

Is Q32 Bio a good buy?

Yes, according to 4 Wall Street analysts, Q32 Bio (FIXX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 50.00% of FIXX's total ratings.

What is FIXX's price target?

Q32 Bio (FIXX) average price target is $2.7 with a range of $2.7 to $2.7, implying a 188.86% from its last price of $0.935. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Q32 Bio stock go up soon?

According to Wall Street analysts' prediction for FIXX stock, the company can go up by 188.86% (from the last price of $0.935 to the average price target of $2.7), up by 188.86% based on the highest stock price target, and up by 188.86% based on the lowest stock price target.

Can Q32 Bio stock reach $1?

FIXX's average twelve months analyst stock price target of $2.7 supports the claim that Q32 Bio can reach $1 in the near future.

What are Q32 Bio's analysts' financial forecasts?

FIXX's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $2M (high $2M, low $2M), average EBITDA is $-2M (high $-2M, low $-2M), average net income is $-1.611M (high $-1.611M, low $-1.611M), average SG&A $25.96M (high $25.96M, low $25.96M), and average EPS is $-0.69 (high $-0.69, low $-0.69).

Did the FIXX's actual financial results beat the analysts' financial forecasts?

Based on Q32 Bio's last annual report (Dec 2023), the company's revenue was $1.16M, which missed the average analysts forecast of $2.85M by -59.37%. Apple's EBITDA was $-101M, beating the average prediction of $-2.845M by 3465.08%. The company's net income was $-113M, beating the average estimation of $-4.021M by 2709.54%. Apple's SG&A was $31.26M, missing the average forecast of $36.93M by -15.36%. Lastly, the company's EPS was $-0.002, missing the average prediction of $-1.722 by -99.88%. In terms of the last quarterly report (Mar 2023), Q32 Bio's revenue was $802K, missing the average analysts' forecast of $1.01M by -20.95%. The company's EBITDA was $-27.286M, beating the average prediction of $-1.015M by 2589.42%. Q32 Bio's net income was $-28.844M, beating the average estimation of $-1.237M by 2231.55%. The company's SG&A was $8.32M, missing the average forecast of $13.17M by -36.78%. Lastly, the company's EPS was $-0.5, missing the average prediction of $-0.53 by -5.66%